Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Novartis to Strengthen Presence in Ophthalmic Field
March 19, 2001
- Teijin: New Blood Glucose Self-Monitoring System
March 19, 2001
- BUSINESS NEWS IN BRIEF -1-
March 19, 2001
- Precious Metals for Dental Use to Be Repriced from April 1
March 19, 2001
- Korosho Issues Brochure on Healthcare Reform to Stimulate Discussions
March 19, 2001
- BUSINESS NEWS IN BRIEF -2-
March 19, 2001
- Fujirebio Aims at No.1 Reagents Maker in 2005
March 19, 2001
- Iwaki, Ohki, Mogi to Operate Joint Distribution System for Retailers
March 19, 2001
- Daiichi Expects to Have Pharmacogenomics Products on the Market in 2012
March 19, 2001
- Chiron, Gen-Probe File Application for HIV-1/HCV Assay
March 19, 2001
- 8 Active Ingredients, Including Herceptin, Zyvox, Recommended for Approval
March 19, 2001
- CQHC to Prepare Standard Format for Ads of Hospital Evaluation Results
March 19, 2001
- Aiming at Drug Sales of \320 Billion in 2004: Mr Bootes of Pfizer
March 19, 2001
- Videx Cap. Included in NHI Price List on Emergency Basis
March 19, 2001
- JPA to Conduct Survey of Endocrine Disruptors
March 19, 2001
- Generics Approved by March 15 to Be Given NHI Prices in July
March 19, 2001
- JPMA to Prepare Guidebooks on New PMS Requirements
March 19, 2001
- LDP Intends to Deal with NHI Prices at First
March 19, 2001
- Kyowa Hakko Aims at Peak Sales of \20 Bil. for Allelock
March 19, 2001
- Need for Self-sufficient Blood Supply System Stressed Again: Red Cross Symposium
March 19, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…